EP Patent

EP4717262A1 — Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

Assigned to Galenicum Health SL · Expires 2026-04-01 · 0y expired

What this patent protects

The present invention provides pharmaceutical compositions comprising tafamidis free acid as the active pharmaceutical ingredient and pharmaceutical dosage forms containing such compositions. These formulations are intended for the treatment and prevention of polyneuropathies, pa…

USPTO Abstract

The present invention provides pharmaceutical compositions comprising tafamidis free acid as the active pharmaceutical ingredient and pharmaceutical dosage forms containing such compositions. These formulations are intended for the treatment and prevention of polyneuropathies, particularly familial amyloid polyneuropathy (FAP) and transthyretin amyloid polyneuropathy (ATTR-PN). The invention also includes processes for the preparation of these dosage forms and methods of treating patients in need of such therapies.

Drugs covered by this patent

Patent Metadata

Patent number
EP4717262A1
Jurisdiction
EP
Classification
—
Expires
2026-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Galenicum Health SL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.